Guardant Health (GH) Rose Following Several Positive News Reports

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P 500 Index fell 4.27% in the first quarter of 2025, marking a sluggish start to the year for the U.S. equities market. On the other hand, bonds offered a measure of stability, as the Bloomberg U.S. Aggregate Bond Index rose 2.78%. Aristotle Atlantic’s Core Equity strategy returned -5.90% gross of fees (-5.99% net of fees) in the quarter, underperforming the S&P 500 Index’s -4.27% total return. The relative underperformance was due to a mix of security selection and allocation effects. In addition, you can check the fund’s top 5 holdings to determine its best picks for 2025.

In its first-quarter 2025 investor letter, Aristotle Atlantic Core Equity Strategy highlighted stocks such as Guardant Health, Inc. (NASDAQ:GH). Guardant Health, Inc. (NASDAQ:GH) is a precision oncology company. The one-month return of Guardant Health, Inc. (NASDAQ:GH) was -4.39%, and its shares gained 156.17% of their value over the last 52 weeks. On April 21, 2025, Guardant Health, Inc. (NASDAQ:GH) stock closed at $42.61 per share with a market capitalization of $5.789 billion.

Aristotle Atlantic Core Equity Strategy stated the following regarding Guardant Health, Inc. (NASDAQ:GH) in its Q1 2025 investor letter:

"Guardant Health, Inc. (NASDAQ:GH) was a relative contributor in the first quarter following several positive announcements and solid fourth quarter earnings. Guardant announced Advanced Diagnostic Laboratory Test (ADLT) pricing from Medicare on its Guardant Shield test and a contract with the VA hospital system to cover patients over 45 years of age. This follows strong momentum and positive full-year revenue guidance."

Guardant Health, Inc. (NASDAQ:GH) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 40 hedge fund portfolios held Guardant Health, Inc. (NASDAQ:GH) at the end of the fourth quarter which was 28 in the previous quarter. Guardant Health, Inc.'s (NASDAQ:GH) fourth quarter revenue increased 30% to $202 million. While we acknowledge the potential of Guardant Health, Inc. (NASDAQ:GH) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

In another article, we covered Guardant Health, Inc. (NASDAQ:GH) and shared the list of best performing mid cap stocks to buy according to analysts. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.

Disclosure: None. This article is originally published at Insider Monkey.